SLC5A2 and chronic kidney disease: SGLT2 inhibitors did not significantly reduce the risk of major renal outcomes in CKD patients with heart failure (eGFR<60 mL/min/1.73 m<sup>2</sup>: HR 0.81, [95% CI 0.47-1.38], I<sup>2</sup> = 0.00%; UACR > 300 mg/g: HR 0.66, [95% CI 0.41-1.07], I<sup>2</sup> = 0.00%).